AiCuris Anti-infective Cures AG
AiCuris develops novel anti-viral therapies to protect immunocompromised patients from life-threatening infections.
Classification
Profile
Funding
Funding details not yet available.
Delivering novel anti-viral therapies specifically designed to meet the critical needs of patients suffering from weakened immune systems.
Patients with compromised immune systems and the healthcare providers treating them within the DACH region and broader international markets.
Product sales (post-approval) - Pritelivir (prescription antiviral) and future AIC468 sales, priced under orphan-drug frameworks (EU 10-year · Licensing royalties - Revenue from partners (e.g., MSD) on co-commercialised products · Milestone payments & upfront fees - From strategic collaborations (Lysando, potential future biotech partners)
Direct sales force - Targeted to transplant centers and large hospitals in Europe & North America · Licensing & co-commercialisation - Partnership with MSD for PREVYMIS® (CMV prophylaxis) demonstrates a viable licensing route for other asse · Scientific congresses & peer-review publications - ID Week, ECCMID, and high-impact journals used to genera
pharmaceutical and biotechnology partners for drug development and commercialization
Likely dominated by high R&D costs associated with developing novel anti-viral therapies, alongside standard operational expenses for a biotech firm.
Proprietary anti-viral therapeutic technologies and a specialized scientific team focused on anti-infective cure development.
Core operations involve the research, development, and clinical validation of novel anti-viral therapeutic treatments for immunocompromised populations.
sales-led, partnerships
Competes with other AI-driven drug discovery platforms and traditional pharmaceutical R&D pipelines in the anti-infective space.
Addressing the lack of effective treatment options for patients with weakened immune systems who are vulnerable to viral infections.
No investors recorded yet.